Seoul National University

Neuracle Science Co., Ltd.

Snur & Db Foundation

National Cancer Center

Other

Korea Research Institute of Bioscience and Biotechnology

Oklahoma Medical Research Foundation

Ewha University-Industry Collaboration Foundation

Institut Pasteur Korea

The Asan Foundation, University of Ulsan Foundation for Industry Cooperation

Kim, Hyun Kee

Junho Chung

Hyori Kim

Junyeong Jin

Bongcheol Kim

Hwa Kyoung Lee

Ki-Hyun Kim

Soohyun Kim

Sunyoung Park

Jae Young Seong

Jong Ik Hwang

Eun Bee Cho

Jee Youn Lee

Won Jun Yang

Tae Young Yune

Miyoung Kim

Ji Eun Kim

Min Soo Kim

Jeong Hun Kim

Jinhee Kim

Dong Sik Kim

Ji Eun Lee

Jae-Keun Lee

Rheal A Towner

Jong Bae Park

Dong Hyun Jo

Su Ui Lee

Kyunglim Lee

In Pyo Choi

Eugene C Yi

Wonkyum Kim

Jae-Gahb Park

Hyung-Bae Park

Jaehoon Jung

Sooyun Lee

Seungtaek Kim

Kyungho Choi

Yumi Oh

Ji-Young Min

Wha Jung Kim

Meehyun Ko

Do Been Hwang

Soo Min Yoon

Aerin Yoon

Hyun Kee Kim

Gunwoo Park

Jung Won Shin

Jungwon Han

Tae-Don Kim

Jeongwon Yoon

Suree Kim

Dongmin Kang

Dobeen Hwang

Myoung-don Oh

Eunhwoi You

Dohoon Lee

Wan Beom Park

Youngmi Hur

The present disclosure is directed to novel monoclonal antibodies that bind to ELTD 1 and methods for use thereof, including, detection and treatment of cancer, multiple sclerosis, retinopathy, or promoting tissue regeneration.

Monoclonal antibodies to ELTD1 and uses thereof

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

The present invention relates to an antibody against a PDGF receptor, an antibody-drug conjugate in which a chemotherapeutic agent is conjugated to the antibody against PDGF receptor, and a use of prevention or treatment of ocular neovascular diseases.

PDGF receptor antibody and use thereof

The present invention relates to an anti-ROS1 antibody improved in specificity for ROS1 and a use thereof and, more particularly, provides an anti-ROS1 antibody or an antigen-binding fragment thereof and a use thereof in cancer diagnosis.

Anti-ROS1 antibody and use thereof

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, antibodies are deimmunized to reduce immunogenicity in a human subject. In some embodiments, the anti-FAM19A5 antibodies can modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, a neuropathic pain, or a cancer, by administering an antibody that specifically binds to human FAM19A5.

Disclosed are a natural killer (NK) cell expressing an anti-cotinine chimeric antigen receptor (CAR) specifically binding to cotinine, and a cell therapeutic agent containing the NK cell. The CAR-expressing NK cell which specifically binds cotinine, can effectively move to tumor tissue, regardless of the kind of cancer, depending on the binding substance bound to cotinine. Therefore, the natural killer cell can be usefully employed as a gene therapy exhibiting a highly efficient anticancer effect.

Natural killer cell expressing anti-cotinine chimeric antigen receptor

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.

Anti-FAM19A5 antibodies and uses thereof

The present invention relates to chimeric antibody receptors with anti-cotinine antibodies linked, and use thereof. A T cell presenting the chimeric antibody receptor on the surface secretes interferon gamma specifically for a target molecule of a cotinine-conjugated binding molecule that is added together therewith and induces cell death of the cell expressing the target molecule by the T cell. On the contrary, by administering a cytotoxic agent conjugated with cotinine, cell death of the chimeric antigen receptor T cell is induced. Therefore, if necessary, a cytotoxic agent conjugated with cotinine can be administered to remove the chimeric antigen receptor T cells that have been already administered, thereby suppressing immune side effects due to hyperactivity of T cells. Thus, the chimeric antigen receptor to which the anti-cotinine antibody is linked can be effectively and safely used for the treatment of cancer.

Chimeric antigen receptor to which anti-cotinine antibody is linked, and use thereof

The present invention relates to an antibody against C5, and a method for preventing and treating complement-related diseases using the antibody, wherein the antibody against C5 is effectively usable in preventing and treating complement-related diseases by inhibiting complement activation.

Anti-C5 antibodies and methods of treating complement-related diseases

The present invention relates to an antibody drug conjugate using a bispecific antibody and its use. The antibody drug conjugate of the present invention can easily form a conjugate of an antibody and a drug without a multistep synthetic process though binding of a conjugate of a bivalent cotinine-peptide and a drug, and an anti-cotinine single chain variable fragment. In addition, the antibody drug conjugate can effectively deliver a drug to a target to which the antibody binds specifically, and can enhance a half-life of a drug in the body, thereby improving a therapeutic effect.

Antibody drug conjugate platform using bispecific antibody

The present invention relates to an antibody which specifically binds to the envelope glycoprotein of severe fever with thrombocytopenia syndrome virus (SFTSV), the pathogen of severe fever with thrombocytopenia syndrome (SFTS), and is used in order to effectively detect or diagnosis SFTSV and treat SFTS.

Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus and use for same

A framework fragment derived from a chicken antibody, in which an amino acid at a particular position is replaced by cysteine, a heavy chain variable region or a light chain variable region including the framework fragment, or an antibody including the heavy chain variable region or the light chain variable region does not induce or prevents formation of disulfide bonds between antibody molecules while maintaining activity and reactivity of the antibody. The antibody introduced with cysteine or an antigen-binding fragment thereof easily binds with a conjugation compound such as a chemotherapeutic drug, an enzyme, an aptamer, a toxin, an affinity ligand, or a detection label, thereby being applied to various fields for diagnosis or treatment of diseases.

Chicken antibody transformed into cysteine and site-specific conjugation using same

The present invention relates to a complex in which an anti-cotinine antibody is bound to a conjugate of a binding material and cotinine, and a use of the complex. The complex according to the present invention may be used as an analysis tool in an in vitro biological assay method, and may retain the specific reactivity and the biological function of the binding material, and the capabilities of inducing complement-mediated cell cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) and a prolonged in vivo half-life, which are intrinsic characteristics of an antibody.

Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof

Growing community of inventors

Seongnam-si, South Korea

Junho Chung